PriceTargets.com logo

Cocrystal Pharma - COCP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 354.55%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.20 As of 07/26/2024 01:00 AM ET
▼ -0.02 (-0.90%)

This chart shows the closing price for COCP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cocrystal Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COCP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COCP

Analyst Price Target is $10.00
▲ +354.55% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cocrystal Pharma in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 354.55% upside from the last price of $2.20.

This chart shows the closing price for COCP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Cocrystal Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
4/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
1/3/2024HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $10.00Low
12/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
10/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
5/24/2023HC WainwrightLower Target$35.00 ➝ $12.00Low
1/24/2023HC WainwrightLower TargetBuy$42.00 ➝ $35.00Low
11/7/2022HC WainwrightBoost TargetBuy$42.00Low
5/12/2022Noble FinancialReiterated RatingBuy$60.00High
3/14/2022HC WainwrightReiterated RatingBuy$48.00Medium
8/23/2021Noble FinancialReiterated RatingBuyC$60.00High
8/3/2021HC WainwrightReiterated RatingBuy$48.00Low
7/30/2021Noble FinancialReiterated RatingBuy$60.00Low
6/15/2021HC WainwrightLower TargetBuy$54.00 ➝ $48.00High
6/11/2021Noble FinancialInitiated CoverageBuyMedium
11/18/2020Noble FinancialReiterated RatingBuy$60.00Low
11/12/2020HC WainwrightLower TargetBuy$60.00 ➝ $54.00High
7/8/2020HC WainwrightReiterated RatingBuyMedium
7/8/2020HC WainwrightInitiated CoverageBuy$60.00High
6/16/2020Noble FinancialInitiated CoverageOutperform$60.00High
(Data available from 7/27/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/27/2024

Current Sentiment

  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Cocrystal Pharma logo
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $2.20
Low: $2.19
High: $2.22

50 Day Range

MA: $2.35
Low: $1.89
High: $2.80

52 Week Range

Now: $2.20
Low: $1.33
High: $3.29

Volume

9,434 shs

Average Volume

22,400 shs

Market Capitalization

$22.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Cocrystal Pharma?

The following Wall Street research analysts have issued stock ratings on Cocrystal Pharma in the last twelve months: HC Wainwright.
View the latest analyst ratings for COCP.

What is the current price target for Cocrystal Pharma?

1 Wall Street analysts have set twelve-month price targets for Cocrystal Pharma in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 354.5%. HC Wainwright has the highest price target set, predicting COCP will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Cocrystal Pharma in the next year.
View the latest price targets for COCP.

What is the current consensus analyst rating for Cocrystal Pharma?

Cocrystal Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe COCP will outperform the market and that investors should add to their positions of Cocrystal Pharma.
View the latest ratings for COCP.

What other companies compete with Cocrystal Pharma?

Other companies that are similar to Cocrystal Pharma include Oncternal Therapeutics, Checkpoint Therapeutics, Tiziana Life Sciences, Anixa Biosciences and Eton Pharmaceuticals. Learn More about companies similar to Cocrystal Pharma.

How do I contact Cocrystal Pharma's investor relations team?

Cocrystal Pharma's physical mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The company's listed phone number is (305) 425-1780 and its investor relations email address is [email protected]. The official website for Cocrystal Pharma is www.cocrystalpharma.com. Learn More about contacing Cocrystal Pharma investor relations.